An Abbvie Inc. investor launched a lawsuit in the Delaware Chancery Court on Friday demanding to see the company’s books and records connected to allegations of safety issues with its testosterone treatment AndroGel that led to a $140 million jury verdict with potentially more lawsuits on the way.